KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Net Cash Flow (2023 - 2025)

Biocryst Pharmaceuticals' Net Cash Flow history spans 9 years, with the latest figure at -$9.5 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 210.8% year-over-year to -$9.5 million; the TTM value through Dec 2025 reached -$16.3 million, down 213.34%, while the annual FY2025 figure was -$16.3 million, 213.34% down from the prior year.
  • Net Cash Flow reached -$9.5 million in Q4 2025 per BCRX's latest filing, down from -$3.6 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $18.0 million in Q3 2024 to a low of -$149.5 million in Q1 2023.
  • Average Net Cash Flow over 3 years is -$18.0 million, with a median of -$4.7 million recorded in 2024.
  • Peak YoY movement for Net Cash Flow: skyrocketed 304.95% in 2024, then tumbled 210.8% in 2025.
  • A 3-year view of Net Cash Flow shows it stood at -$40.6 million in 2023, then surged by 121.11% to $8.6 million in 2024, then crashed by 210.8% to -$9.5 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Net Cash Flow are -$9.5 million (Q4 2025), -$3.6 million (Q3 2025), and -$3.3 million (Q2 2025).